Sign Out
Etoricoxib is contraindicated in patients with: Hypersensitivity to any component of this product. A history of asthma, urticaria, or other allergic reactions after taking aspirin or other NSAIDs.
Congestive heart failure (NYHA II-IV).
Patients with hypertension whose blood pressure is persistently elevated above 140/90mmHg and has not been adequately controlled.
Established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease (including patients who have recently undergone coronary artery bypass graft surgery or angioplasty).
Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score ≥10, see footnote as follows) active peptic ulceration or gastrointestinal (GI) bleeding.
Estimated creatinine clearance < 30mL/min.
Etoricoxib should not be used as adjunctive therapy with other NSAIDs due to the absence of any evidence demonstrating synergistic benefits and the potential for additive adverse reactions.
[The Child-Pugh score employs five clinical measures of liver disease - bilirubin, serum albumin, INR, ascites and hepatic encephalopathy. Each measure is scored 1-3, with 3 indicating most severe derangement. The individual scores are tallied to derive the Child-Pugh score.]
